Reporting period January – March

  · Order intake rose by 3.0% to SEK 5,968 M (5,795), and grew organically by
1.8%

  · Net sales increased by 8.0% to SEK 5,664 M (5,246), and grew organically by
6.6%

  · Profit before tax declined by 55.8% to SEK 252 M (570). Profit was charged
with SEK 240 M (0) in restructuring costs.

  · Earnings per share decreased by 56.8% to SEK 0.76 (1.76)

  · EBITA before restructuring declined by 7.3% to SEK 792 M (854). Adjusted for
currency effects and the Medical Device Tax introduced in the US, EBITA rose by
8%

First quarter 2013

While demand for the Group’s medical-technical capital goods continues to
experience a challenge in the Western European market, which has yet to hit
bottom, volume expectations in the markets outside Western Europe improved
during the quarter. Work on strengthening the Group’s competitiveness and
profitability continue, and a number of efficiency enhancement projects were
initiated during the quarter.

Orders received

The Group’s order intake increased organically by 1.8% during the quarter. For
the Group’s largest business area, Medical Systems, order intake grew
organically by a highly favourable 7.5%, with strong growth in the
Cardiovascular and Critical Care division. For Extended Care, which has
considerable exposure to the elderly care sector and the more mature Western
European and North American markets, order intake declined organically by 4.2%.
In Infection Control, order intake declined organically by 4.6%. While a weaker
Life Science market resulted in a volume decline for Infection Control, demand
from hospital customers experienced a strong trend.

Demand in the Western European markets remains challenging and difficult to
assess, particularly in terms of the southern European markets. The North
American market has stabilized and all business areas reported a positive volume
trend in the US during the quarter. The demand scenario remains robust in the
markets outside Western Europe and North America.

Teleconference with CEO Johan Malmquist and CFO Ulf Grunander
17 April 2013 at 3:00 p.m. Swedish time

Swedish dial in number: +46 8 5853 6965
UK dial in number: +44 20 3478 5300
US dial in number: +1 212 444 0412

Participant passcode: 224195

GETINGE GROUP is a leading global provider of products and systems that
contribute to quality enhancement and cost efficiency within healthcare and life
sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and
MAQUET. ArjoHuntleigh focuses on patient mobility and wound management
solutions. GETINGE provides solutions for infection control within healthcare
and contamination prevention within life sciences. MAQUET specializes in
solutions, therapies and products for surgical interventions, interventional
cardiology and intensive care.

The information is such that Getinge AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.